{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:06:30Z","timestamp":1785769590695,"version":"3.56.0"},"reference-count":88,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our understanding of the pathogenesis and heterogeneity of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) has been dramatically enhanced by recent attempts to profile molecular features of these lymphomas. In this article, we discuss ways in which testing for molecular features may impact DLBCL and FL management if clinical trials are designed to incorporate such tests. Specifically, we discuss how distinguishing lymphomas on the basis of cell-of-origin subtypes or the presence of other molecular features is prognostically and therapeutically significant. Conversely, we discuss how the molecular similarities of DLBCL and FL have provided insight into the potential of both DLBCL and FL cases to respond to agents targeting alterations they have in common. Through these examples, we demonstrate how the translation of our understanding of cancer biology into improvements in patient outcomes depends on analyzing the molecular correlates of treatment outcomes in clinical trials and in routinely treated patients.<\/jats:p>","DOI":"10.1182\/blood-2015-07-658401","type":"journal-article","created":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T02:43:44Z","timestamp":1444272224000},"page":"181-186","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma"],"prefix":"10.1182","volume":"127","author":[{"given":"Julia R.","family":"Pon","sequence":"first","affiliation":[{"name":"Canada\u2019s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Marra","sequence":"additional","affiliation":[{"name":"Canada\u2019s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada; and"},{"name":"Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111903001006100_B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/PAP.0000000000000065","article-title":"Aggressive B-cell lymphomas: a review and practical approach for the practicing pathologist.","volume":"22","author":"Schmidt","year":"2015","journal-title":"Adv Anat Pathol"},{"issue":"6769","key":"2019111903001006100_B2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"7","key":"2019111903001006100_B3","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.leu.2404737","article-title":"The dynamics of the B follicle: understanding the normal counterpart of B-cell-derived malignancies.","volume":"21","author":"Sagaert","year":"2007","journal-title":"Leukemia"},{"issue":"17","key":"2019111903001006100_B4","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111903001006100_B5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2014-05-575092","article-title":"Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?","volume":"125","author":"Dunleavy","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019111903001006100_B6","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas.","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903001006100_B7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111903001006100_B8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2014.05.002","article-title":"Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.","volume":"14","author":"Read","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2019111903001006100_B9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111903001006100_B10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/labinvest.2014.136","article-title":"Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR.","volume":"95","author":"Xue","year":"2015","journal-title":"Lab Invest"},{"key":"2019111903001006100_B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmoldx.2015.01.007","article-title":"Accurate classification of germinal center B-cell-like\/activated B-cell-like diffuse large B-cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay: a CALYM study.","author":"Mareschal","year":"2015","journal-title":"J Mol Diagn"},{"issue":"2","key":"2019111903001006100_B12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/10428190601059746","article-title":"Follicular lymphoma: a historical overview.","volume":"48","author":"van Besien","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"8 Suppl 16","key":"2019111903001006100_B13","first-page":"18","article-title":"Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.","volume":"12","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"2019111903001006100_B14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13487","article-title":"Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies.","volume":"170","author":"Roberts","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111903001006100_B15","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1021\/ja410934b","article-title":"The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure.","volume":"136","author":"Kendrick","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"18","key":"2019111903001006100_B16","doi-asserted-by":"crossref","first-page":"11593","DOI":"10.1073\/pnas.182256799","article-title":"Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription.","volume":"99","author":"Siddiqui-Jain","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"40","key":"2019111903001006100_B17","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains.","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111903001006100_B18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc.","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"7","key":"2019111903001006100_B19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.","volume":"21","author":"Boi","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111903001006100_B20","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.18632\/oncotarget.3343","article-title":"Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2019111903001006100_B21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.4446","article-title":"CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.","volume":"235","author":"Moreno","year":"2015","journal-title":"J Pathol"},{"issue":"1","key":"2019111903001006100_B22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.2012.09123.x","article-title":"A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.","volume":"158","author":"Lee","year":"2012","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111903001006100_B23","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-14-0154","article-title":"Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).","volume":"20","author":"Matas-C\u00e9spedes","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111903001006100_B24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2012.075184","article-title":"Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.","volume":"98","author":"Barnes","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"2019111903001006100_B25","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111903001006100_B26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111903001006100_B27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cell.2011.09.035","article-title":"The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.","volume":"147","author":"Oricchio","year":"2011","journal-title":"Cell"},{"issue":"12","key":"2019111903001006100_B28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"issue":"6","key":"2019111903001006100_B29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.12991","article-title":"Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.","volume":"166","author":"Craig","year":"2014","journal-title":"Br J Haematol"},{"key":"2019111903001006100_B30","author":"Wilson"},{"issue":"9","key":"2019111903001006100_B31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111903001006100_B32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.seminhematol.2015.01.007","article-title":"Novel targeted therapies in diffuse large B-cell lymphoma.","volume":"52","author":"Mehta-Shah","year":"2015","journal-title":"Semin Hematol"},{"issue":"4","key":"2019111903001006100_B33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-013-1979-7","article-title":"Accelerated therapeutic progress in diffuse large B cell lymphoma.","volume":"93","author":"Cai","year":"2014","journal-title":"Ann Hematol"},{"issue":"10","key":"2019111903001006100_B34","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.humpath.2014.06.019","article-title":"Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.","volume":"45","author":"Xerri","year":"2014","journal-title":"Hum Pathol"},{"issue":"17","key":"2019111903001006100_B35","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111903001006100_B36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2141.2003.04086.x","article-title":"Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes.","volume":"120","author":"Horsman","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903001006100_B37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9440(10)63284-1","article-title":"BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.","volume":"165","author":"Iqbal","year":"2004","journal-title":"Am J Pathol"},{"issue":"25","key":"2019111903001006100_B38","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJM198806233182502","article-title":"Expression in non-Hodgkin\u2019s lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.","volume":"318","author":"Ngan","year":"1988","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903001006100_B39","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1172\/JCI72415","article-title":"Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.","volume":"124","author":"Sungalee","year":"2014","journal-title":"J Clin Invest"},{"issue":"20","key":"2019111903001006100_B40","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111903001006100_B41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","article-title":"BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.","volume":"24","author":"Iqbal","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111903001006100_B42","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111903001006100_B43","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111903001006100_B44","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.humpath.2013.06.013","article-title":"Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.","volume":"44","author":"Maeshima","year":"2013","journal-title":"Hum Pathol"},{"issue":"4","key":"2019111903001006100_B45","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2019111903001006100_B46","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111903001006100_B47","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111903001006100_B48","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/leu.2008.230","article-title":"Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL).","volume":"22","author":"Klapper","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111903001006100_B49","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience.","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111903001006100_B50","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1002\/cncr.28899","article-title":"MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.","volume":"120","author":"Petrich","year":"2014","journal-title":"Cancer"},{"issue":"28","key":"2019111903001006100_B51","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"28","key":"2019111903001006100_B52","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111903001006100_B53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.13276","article-title":"A clinician\u2019s guide to double hit lymphomas.","volume":"168","author":"Cheah","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111903001006100_B54","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1021\/ja4109352","article-title":"The transcriptional complex between the BCL2 i-motif and hnRNP LL is a molecular switch for control of gene expression that can be modulated by small molecules.","volume":"136","author":"Kang","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"13","key":"2019111903001006100_B55","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/MCB.01341-10","article-title":"The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.","volume":"31","author":"Rahman","year":"2011","journal-title":"Mol Cell Biol"},{"issue":"9","key":"2019111903001006100_B56","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-13-0114","article-title":"Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.","volume":"11","author":"Sison","year":"2013","journal-title":"Mol Cancer Res"},{"key":"2019111903001006100_B57","first-page":"1347","article-title":"Emerging targets in cancer management: role of the CXCL12\/CXCR4 axis.","volume":"6","author":"Cojoc","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"4","key":"2019111903001006100_B58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4161\/cc.6.4.3837","article-title":"Phosphatidylinositol 3-kinase (PI3K) signaling and regulation of the antibody response.","volume":"6","author":"Omori","year":"2007","journal-title":"Cell Cycle"},{"key":"2019111903001006100_B59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/1471-2407-14-565","article-title":"Constitutive AKT activation in follicular lymphoma.","volume":"14","author":"Yahiaoui","year":"2014","journal-title":"BMC Cancer"},{"issue":"30","key":"2019111903001006100_B60","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019111903001006100_B61","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1074\/mcp.M700596-MCP200","article-title":"A portrait of tissue phosphoprotein stability in the clinical tissue procurement process.","volume":"7","author":"Espina","year":"2008","journal-title":"Mol Cell Proteomics"},{"issue":"11","key":"2019111903001006100_B62","doi-asserted-by":"crossref","first-page":"e113608","DOI":"10.1371\/journal.pone.0113608","article-title":"Immunohistochemistry of colorectal cancer biomarker phosphorylation requires controlled tissue fixation.","volume":"9","author":"Theiss","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"2019111903001006100_B63","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/gcc.22126","article-title":"Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.","volume":"53","author":"Bohers","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2019111903001006100_B64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"5","key":"2019111903001006100_B65","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"2019111903001006100_B66","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"1","key":"2019111903001006100_B67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrd4175","article-title":"Therapeutic targeting of EPH receptors and their ligands.","volume":"13","author":"Boyd","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2019111903001006100_B68","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma.","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111903001006100_B69","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation.","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Reports"},{"issue":"2","key":"2019111903001006100_B70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.beha.2011.02.006","article-title":"Transformation of follicular lymphoma.","volume":"24","author":"Lossos","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"26","key":"2019111903001006100_B71","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111903001006100_B72","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.114.149625","article-title":"18F-FDG or 3\u2032-deoxy-3\u2032-18F-fluorothymidine to detect transformation of follicular lymphoma.","volume":"56","author":"Wondergem","year":"2015","journal-title":"J Nucl Med"},{"issue":"4","key":"2019111903001006100_B73","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","article-title":"The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.","volume":"154","author":"Czuczman","year":"2011","journal-title":"Br J Haematol"},{"key":"2019111903001006100_B74","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1038\/bcj.2015.18","article-title":"Histologically transformed follicular lymphoma exhibits protein profiles different from both non-transformed follicular and de novo diffuse large B-cell lymphoma.","volume":"5","author":"Ludvigsen","year":"2015","journal-title":"Blood Cancer J"},{"issue":"15","key":"2019111903001006100_B75","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas.","volume":"362","author":"Lenz","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903001006100_B76","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.28.11.1","article-title":"Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.","volume":"11","author":"Lam","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2019111903001006100_B77","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"2019111903001006100_B78","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.14694\/EdBook_AM.2015.35.e458","article-title":"Cell-of-origin in diffuse large B-cell lymphoma: are the assays ready for the clinic?","volume":"35","author":"Scott","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"22","key":"2019111903001006100_B79","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"2019111903001006100_B80","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"5870","key":"2019111903001006100_B81","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"7277","key":"2019111903001006100_B82","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"3","key":"2019111903001006100_B83","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies.","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2019111903001006100_B84","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma.","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111903001006100_B85","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111903001006100_B86","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111903001006100_B87","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.12915","article-title":"Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.","volume":"166","author":"Evens","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111903001006100_B88","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/2\/181\/1351703\/181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/2\/181\/1351703\/181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T01:40:29Z","timestamp":1692063629000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/2\/181\/34822\/Clinical-impact-of-molecular-features-in-diffuse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,14]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-07-658401","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,14]]}}}